Personal Capital Advisors Corp Takes $375,000 Position in Core Laboratories (CLB)

Share on StockTwits

Personal Capital Advisors Corp bought a new stake in Core Laboratories (NYSE:CLB) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 3,234 shares of the oil and gas company’s stock, valued at approximately $375,000.

Several other hedge funds have also modified their holdings of CLB. Dimensional Fund Advisors LP boosted its holdings in shares of Core Laboratories by 3.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 277,192 shares of the oil and gas company’s stock valued at $29,998,000 after purchasing an additional 8,287 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in shares of Core Laboratories by 3.1% in the 1st quarter. Principal Financial Group Inc. now owns 187,270 shares of the oil and gas company’s stock valued at $20,266,000 after purchasing an additional 5,657 shares in the last quarter. BB&T Securities LLC boosted its holdings in shares of Core Laboratories by 21.5% in the 1st quarter. BB&T Securities LLC now owns 21,504 shares of the oil and gas company’s stock valued at $2,327,000 after purchasing an additional 3,810 shares in the last quarter. Allianz Asset Management GmbH boosted its holdings in shares of Core Laboratories by 36.4% in the 1st quarter. Allianz Asset Management GmbH now owns 76,545 shares of the oil and gas company’s stock valued at $8,284,000 after purchasing an additional 20,410 shares in the last quarter. Finally, UBS Group AG boosted its holdings in shares of Core Laboratories by 32.6% in the 1st quarter. UBS Group AG now owns 18,842 shares of the oil and gas company’s stock valued at $2,039,000 after purchasing an additional 4,629 shares in the last quarter.

Several equities research analysts recently weighed in on the company. Piper Jaffray Companies set a $95.00 price objective on Core Laboratories and gave the company a “hold” rating in a report on Friday, October 5th. Morgan Stanley assumed coverage on Core Laboratories in a report on Tuesday, September 18th. They set an “equal weight” rating and a $125.00 price objective on the stock. Citigroup downgraded Core Laboratories from a “neutral” rating to a “sell” rating in a report on Monday, July 2nd. JPMorgan Chase & Co. raised their price objective on Core Laboratories from $118.00 to $121.00 and gave the company an “overweight” rating in a report on Monday, September 17th. Finally, Stifel Nicolaus assumed coverage on Core Laboratories in a report on Monday, September 10th. They set a “hold” rating and a $117.00 price objective on the stock. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $115.15.

NYSE CLB opened at $107.25 on Friday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.85 and a current ratio of 2.24. Core Laboratories has a twelve month low of $87.66 and a twelve month high of $130.34. The firm has a market cap of $5.12 billion, a P/E ratio of 53.29, a PEG ratio of 3.96 and a beta of 1.46.

Core Laboratories (NYSE:CLB) last announced its earnings results on Wednesday, July 25th. The oil and gas company reported $0.59 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.59. The firm had revenue of $175.48 million for the quarter, compared to the consensus estimate of $174.47 million. Core Laboratories had a return on equity of 64.13% and a net margin of 13.32%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business earned $0.51 EPS. On average, analysts forecast that Core Laboratories will post 2.44 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 20th. Shareholders of record on Friday, October 19th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.05%. The ex-dividend date is Thursday, October 18th. Core Laboratories’s payout ratio is presently 110.00%.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

See Also: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply